THIS LINK WILL TAKE YOU TO A SITE MAINTAINED BY A THIRD PARTY WHO IS SOLELY RESPONSIBLE FOR ITS CONTENTS
VBI Vaccines provides this link as a service to website visitors. VBI Vaccines is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Demographic and baseline characteristics were similar in both vaccine groups.
The primary objective was to demonstrate consistency of immune response as measured by geometric mean concentration of antibodies across three consecutively manufactured lots of PreHevbrio 10 μg. The secondary objective was to demonstrate non-inferiority of SPR (% of subjects achieving anti-HBs titers ≥10 mIU/mL) of PreHevbrio (pooled) compared to Engerix-B at Day 196.
Demographic and baseline characteristics were similar in both vaccine groups.
The two co-primary objectives of comparing SPR (% of subjects achieving anti-HBs titers ≥10 mIU/mL) at 4 weeks after receiving the third dose of PreHevbrio or Engerix-B were non-inferiority in adults ≥18 years of age and superiority in adults ≥45 years of age for PreHevbrio 10 μg compared to Engerix-B 20 μg. Key secondary endpoints included SPRs for PreHevbrio at days 56 and 168 and for Engerix-B at day 196; local and systemic solicited adverse events; and unsolicited adverse events. Key exploratory endpoints included SPRs for both study groups at days 0, 28, 56, 168, and 336; geometric mean concentration of anti-HBs antibody titers; and the proportion of participants having anti-HBs titers ≥100 mIU/mL at days 28, 56, 168, 196, and 336.
